Sonic Incytes Medical Corp.

Sonic Incytes Medical Corp. is a Canadian-based startup committed to revolutionizing patient care through innovative diagnostic solutions. Their flagship product, VELACUR, is a point-of-care AI-guided ultrasound elastography designed to aid in the management of chronic liver diseases such as MASLD and MASH. This advanced liver imaging tool provides real-time, AI-guided quantification of key markers for fatty liver disease—liver stiffness and attenuation. With an affordable upfront cost and accessibility, VELACUR aims to address the growing epidemic of fatty liver disease by making liver imaging at the point of care more accessible. Founded in 2017, Sonic Incytes operates in the Health Care and Medical Devices industries. The startup recently secured a $7.30M Series A investment on 07 December 2021, backed by an impressive group of investors including Gaingels, INP Capital, MEDTEQ+, Wavemaker 360, MINT Venture Partners, Ginkgo Capital, Nimbus Synergies Inc., and Nicola Wealth Management. This significant investment not only demonstrates confidence in Sonic Incytes' innovative approach to liver disease diagnostics but also provides the necessary financial support for future growth and development.